HER2+ Breast Cancer Treatment Dynamics and Challenges

Opinion
Video

Health care professionals discuss the evolving landscape of HER2+ breast cancer treatments, delving into the complexities of the HER2CLIMB trial and strategies for third- and fourth-line interventions.

This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.

O’Shaughnessy and Rugo discuss the HER2CLIMB-02 trial, summarizing its key findings and considering its place in the treatment algorithm. The trial, conducted in a different era, focused on a second-line setting, comparing T-DM1 (trastuzumab emtansine) plus or minus tucatinib in patients with HER2-positive breast cancer. The results demonstrated a significant improvement in median progression-free survival, especially in the subset with brain metastases. The trial’s unique aspects include a diverse patient population with varying lines of prior therapy.

Isaacs emphasizes the importance of survival data and expresses a preference for the HER2CLIMB regimen due to the established phase 3 trial. Rugo adds insights about the trial’s context, highlighting the changing treatment landscape and the need for access to effective therapies globally.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Video 4 - "Challenges in Adopting Targeted Therapies for BRAF Alterations"
Video 3 - "BRAF V600E Mutant Ganglioglioma"
Video 10 - "SELECT Trial & DECISION Trial Outcomes and Lessons Learned"
Video 9 - "Identifying RAI-Refractory Disease: A Key Aspect of DTC Management"
Video 18 - "Future Perspectives and Unmet Needs in Renal Cell Carcinoma"
Video 17 - "Nivolumab Plus Cabozantinib in Non–Clear Cell RCC"
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Video 16 - "Trajectory of Evolving HCC Treatment Landscape"
Related Content